Ivermectin and Cancer: The Appeal, the Evidence, and the Risks Patients Should Know About

Almost every week, a new patient asks me about ivermectin. Usually, they have read a testimonial, watched a video, or been handed a dosing schedule by a friend who swears by it. Sometimes they have already started and are telling me only now. I understand the pull completely. When you have been told your cancer is advanced, the idea that an inexpensive, decades-old, widely available medication might be quietly doing something powerful is deeply appealing. And that appeal isn’t built on nothing. The laboratory work is interesting.

That is exactly why this conversation deserves more precision than it usually gets, not less. What follows is not an argument that ivermectin is worthless, and it is certainly not a dismissal of your desire to do everything possible. It is an accounting of what the science actually shows, where the numbers stop lining up, and why the risk picture changes substantially when a drug taken once or twice a year for parasites gets taken at many times that dose, every day, for months, by someone whose liver, immune system, and gut are already under strain.

What the laboratory research actually shows

Cell and animal studies have reported that ivermectin interferes with several processes that matter in cancer biology, including mitochondrial function, certain growth-signaling pathways, and the pumps tumor cells use to expel chemotherapy. One of the most intriguing findings came from City of Hope, where ivermectin induced a form of tumor cell death that recruits T cells into the tumor, and where combining ivermectin with an anti-PD1 checkpoint antibody shrank breast tumors in mice, even though neither drug worked alone. That is a real result in a real journal, and it is the reason serious researchers are interested.

The problem is the concentration at which these effects appear. Cell studies typically show meaningful activity in the low micromolar range. In the macrophage study by Zhang and colleagues, for instance, the concentration that cut cell viability in half was 7.34 micromolar at 24 hours and 4.49 micromolar at 48 hours.

Now compare that with what actually circulates in a person. In the landmark safety study by Guzzo and colleagues, healthy volunteers given a single 120 mg dose, roughly 10 times the highest FDA-approved dose on a weight-adjusted basis, reached a peak blood level of about 247.8 ng/mL. Given ivermectin’s molecular weight of roughly 875, that works out to about 0.28 micromolar, well below the range where most of the interesting laboratory effects were seen. This is the same arithmetic problem that eventually sank the COVID-19 hypothesis: the concentration needed to reproduce the antiviral effect in a dish was calculated at roughly 35 times the maximum approved plasma concentration.

This does not prove ivermectin cannot help anyone. Tumor tissue levels are not blood levels, and some effects may occur at lower concentrations than those measured in a dish. But it does mean that reasoning from “it killed cancer cells in the lab” to “therefore I should take it” skips the step where the dose has to be reachable in a living body without breaking something else.

Why “safe for deworming” is not the same as “safe at cancer doses”

Ivermectin’s reputation for safety was earned in a specific setting: single or infrequent doses, in otherwise healthy people, for parasitic infection. Guzzo’s volunteers tolerated large single doses with mostly headache, dizziness, and stomach upset. That is a real safety record, and I do not dismiss it.

The high-dose, long-duration pattern is a different pharmacological situation, for three reasons.

First, the body’s handling of the drug stops being predictable at high doses. The enzymes that break ivermectin down and the pumps that move it out of tissues begin to saturate, so doubling the dose can more than double the tissue exposure. Marjanović and colleagues gave rats 3-24 times the standard antiparasitic dose for only 5 days and found microscopic damage in liver, kidney, testes, and brain, along with elevated liver enzymes, despite minimal outward signs of illness. That last detail matters enormously if you are dosing yourself at home: the animals looked fine.

Second, food changes everything. Taking ivermectin with a high-fat meal increases absorption roughly 2.5-fold. Many circulating protocols instruct exactly this, which means real exposure is often considerably higher than the milligram number suggests.

Third, duration matters. In a review of 37 poison center cases, Hoang and colleagues described a distinct chronic pattern: people taking smaller daily doses over weeks developed milder neurological and digestive symptoms rather than dramatic crises. Milder is not the same as absent, and a few weeks is shorter than most cancer regimens people attempt.

Your blood-brain barrier is the safety margin, and it is not guaranteed

Ivermectin is comparatively gentle in humans because the nervous system is protected by a barrier with an active pump built into it. A protein called P-glycoprotein sits in the blood vessels of the brain and pushes ivermectin back into the bloodstream before it can accumulate in nerve tissue. This is an elegant design, and it does quiet work every time someone takes a dose without incident.

It is also the single point of failure. Baudou and colleagues documented a 13-year-old boy who developed coma and neurological deficits after a single ordinary dose of 0.23 mg/kg, because he happened to carry two faulty copies of the gene for that pump. Chandler’s analysis of the World Health Organization’s global safety database identified encephalopathy, seizures, unsteadiness, and coma occurring within hours to days of standard dosing, including in patients without the tropical parasite co-infection long blamed for such events.

Several things can weaken that barrier or overwhelm that pump, and cancer patients are disproportionately exposed to all of them: systemic inflammation, brain metastases, prior cranial radiation, high cumulative dosing that saturates the pump, and a long list of common medications that block it. Hoang and colleagues specifically found amplified neurotoxicity in patients also taking macrolide antibiotics, proton pump inhibitors, and certain beta-blockers. Proton pump inhibitors alone are on the medication list of a large share of oncology patients.

There is also no antidote. Treatment of ivermectin neurotoxicity is supportive care while the body clears the drug.

The liver is where I worry most, and there are now published cases

The liver breaks down ivermectin almost entirely, primarily through the CYP3A4 enzyme system, which is also the main route for a large share of oral cancer medications.

The animal data are consistent. Belo and colleagues gave mice ivermectin for 7 consecutive days and found swelling of liver cells and inflammatory infiltrates, with markedly worse liver damage when the animals were then exposed to infection. That escalation concerns me, because infection is not rare when white counts are low.

The human cases are no longer hypothetical. In 2026, Powderly and colleagues reported a 65-year-old man with prostate cancer who took veterinary fenbendazole and ivermectin daily for about 3 months on the advice of an online cancer support group. He developed jaundice, fatigue, and abdominal pain, with an ALT of 1764 U/L, an AST of 1132 U/L, and a bilirubin of 12.9 mg/dL. A formal causality assessment rated the anthelmintics as the highly probable cause. He recovered after stopping, with liver tests normalizing over about 6 weeks. Thakurdesai and colleagues reported a 67-year-old woman with a history of colon cancer whose liver biopsy confirmed severe injury after self-administered fenbendazole, with an ALT of 2600 U/L and a bilirubin of 13.3 mg/dL, taking 3 months to normalize.

Add these possibilities to a patient who may already have liver metastases, an elevated ALT from chemotherapy, or a targeted drug with its own liver signal, and the margin narrows quickly. Nobody dosing themselves at home is checking liver enzymes every few weeks, and the rat data show that measurable organ injury can precede any symptoms at all.

The interaction problem almost nobody discusses

This is the piece most patients have never heard, and in my judgment it is the most under-appreciated risk of all.

Ivermectin isn’t handled only by CYP3A4. It also interacts with the transport pumps that move drugs in and out of cells, and it does so in both directions. Rendic’s detailed review established that ivermectin is a CYP3A4 substrate, a weak inhibitor of several other liver enzymes, and a substrate of the P-glycoprotein pump. Pouliot and colleagues showed that ivermectin is a potent blocker of that pump in drug-resistant tumor cells, which could in theory let more chemotherapy into a cancer cell. But Ménez and colleagues showed that ivermectin also increases production of that same pump in liver cells, which could, in theory, push drugs out faster.

Both of those are laboratory findings, and both directions are plausible. What that means practically is simple and uncomfortable: nobody knows what adding chronic high-dose ivermectin does to the blood levels of your specific cancer treatment. It could raise them, lower them, or do nothing, and no one has measured the effect in patients. For someone taking an oral targeted therapy or a hormonal agent with a narrow effective range, that is not a small unknown.

The picture gets more complicated with supplements, because the same enzyme and pump are affected by many things people in integrative care take. Grapefruit, quercetin, curcumin with piperine, berberine, green tea extract, and high-dose vitamin E all interact with these systems, while St John’s wort strongly accelerates them. The widely circulated protocols combine high-dose ivermectin with fenbendazole or mebendazole, vitamin D, curcumin, CBD, and several other agents at once. That is a large stack of interacting compounds layered on top of an actual cancer regimen, with no interaction testing behind it. Standard interaction references also flag ivermectin as capable of raising the INR in people taking warfarin, which matters because blood clots are common in cancer and many patients are anticoagulated.

Cancer itself changes how your body handles the drug

Here is a detail that almost never makes it into online protocols. Ivermectin is about 93% bound to proteins in the blood. Only the unbound fraction is active. Klotz and colleagues, who first measured this in 1990, specifically warned that in malnutrition or in any condition where blood proteins fall, a higher free fraction should be expected.

Low albumin, muscle loss, and cachexia are exactly the conditions that raise that free fraction, and they are common in advanced cancer. Ivermectin is also highly fat-soluble and distributes into body fat, so significant weight loss changes where the drug goes and how long it lingers. Liver metastases or impaired liver function plausibly slow its clearance, and here the honest answer is that the pharmacokinetics have never been studied in liver impairment at all, which is why the prescribing information offers no dose adjustment. Vomiting, diarrhea, prior stomach or bowel surgery, and malabsorption all change absorption in ways nobody can predict from a milligram-per-kilogram formula on a website.

In other words, the same dose that a healthy 180-pound adult tolerates may not behave the same way in a patient who has lost 30 pounds and whose albumin is low.

Immune cells, the gut, and other reported harms

The Zhang macrophage study is uncomfortable reading for anyone taking ivermectin alongside immunotherapy. In mouse macrophages, ivermectin reduced cell survival, caused DNA breaks and oxidative damage, triggered cell death, suppressed the cells’ ability to engulf and clear debris, and drove large increases in inflammatory signals, with IL-6 up more than 18-fold and TNF-alpha nearly 9-fold at the highest concentration tested. Those concentrations are higher than oral dosing achieves in blood, and cells in a dish are not a human immune system, so I will not overstate it. But macrophages are frontline immune cells, and their function is part of what a patient on checkpoint inhibitor therapy is depending on.

In the gut, Belo and colleagues found that 7 days of oral ivermectin in mice cut several major bacterial groups substantially, with reductions of roughly 20% in Bacteroidetes, 56% in Firmicutes, 66% in Proteobacteria, and 71% in Tenericutes, while Akkermansia rose from 1.58% to 11.59% of the community. The cecal contents from these animals were measurably more inflammatory, and the intestinal lining itself showed structural disruption. The follow-up review from the same group is appropriately measured, noting that findings vary by species and dose and that a human colon-simulation study did not show lasting imbalance. Still, gut bacterial composition is now known to influence response to immunotherapy, making unmeasured microbiome effects an unattractive trade-off for an unproven benefit.

Other documented reactions deserve brief mention. Reviewing FDA adverse event reports from 2014 to 2021, Bomze and colleagues identified 517 reports involving systemic ivermectin, of which 25 were severe skin reactions, including 7 cases of toxic epidermal necrolysis and 7 of Stevens-Johnson syndrome. Five of those 25 patients died. These reactions are rare but real, and in transplant or immunotherapy patients they can also be mistaken for other conditions.

When the drug hides the problem

There is a specific way ivermectin can cost you your treatment without ever poisoning you badly, and it is worth understanding.

Yamaguchi and colleagues described an 80-year-old woman with lung cancer on pembrolizumab who developed abnormal liver tests after starting fenbendazole on her own. Her enzymes resolved within 6 weeks of stopping the anthelmintic, and importantly, she could continue pembrolizumab. Had the team not learned about the supplement, the obvious conclusion would have been immune-related hepatitis from the immunotherapy, which typically means steroids and often permanent discontinuation of a drug that was working.

That is the quiet danger. Undisclosed use does not just risk direct harm. It corrupts the interpretation of every abnormal lab that follows.

What you may be giving up

Two more consequences belong in the decision.

The first is clinical trial eligibility. Trial protocols routinely exclude patients taking strong inhibitors or inducers of CYP3A4 and P-glycoprotein, and many exclude any concurrent unapproved anticancer therapy. Taking ivermectin for cancer can therefore close the door on a trial that might be the best available option later.

The second is the largest risk in this entire discussion, and it has nothing to do with liver enzymes. Johnson and colleagues examined 281 patients with curable breast, prostate, lung, or colorectal cancer who chose alternative medicine instead of conventional treatment. Their risk of death was two and a half times higher, with 5-year survival of 54.7% compared with 78.3%. A companion study found that patients using complementary medicine also had roughly double the risk of death, and that the excess risk was explained by their higher rate of refusing or delaying standard treatment. The danger was not the herb or the pill. It was the delay.

Nondisclosure compounds this. In a national survey, about a third of patients and survivors used complementary or alternative medicine, and 29.3% did not tell their physician, most often because nobody asked.

Product quality is its own risk

Much of the severe toxicity in the published record traces to what people actually swallowed rather than to the molecule itself. Temple and colleagues documented a surge of poison center cases centered on 1.87% equine paste and 1% livestock solutions, with hospitalizations and intensive care admissions. When Belgian regulators analyzed 19 seized or online-purchased ivermectin samples, none met quality standards. They were either systematically underdosed or severely contaminated with bacteria, including two with organisms that cause gastrointestinal illness. For someone whose white count is suppressed, that contamination is not a footnote.

Veterinary products are concentrated for animals that weigh many times what a person does, and they are not made to human pharmaceutical standards. No version of this is worth the savings.

Where the science is actually going

Here is the encouraging part, and it deserves as much attention as the warnings. The right answer is already underway. A phase I/II trial is testing ivermectin combined with checkpoint immunotherapy in metastatic triple-negative breast cancer, with preliminary results from the first nine patients presented in 2025, and a randomized phase II study in solid tumors was slated to begin in 2026. That is how a promising laboratory signal becomes an answer.

In May 2026, the American Society of Clinical Oncology issued a clinical notice stating that ivermectin and fenbendazole should not be used to treat cancer, or as an adjunct to established cancer therapy, outside the safeguards of a well-designed clinical trial, citing the lack of established benefit alongside the potential for toxicity and harmful drug interactions. That is the recommendation of the largest professional body in oncology, and it is worth taking at full weight. A trial is not a workaround for obtaining the drug. It is the setting where the question of whether ivermectin helps anyone with cancer will finally be answered, under monitoring far closer than anything available outside one.

What supervision can and cannot catch

When a patient tells me they are determined to try ivermectin anyway, my goal is not to win an argument. It is to reduce the harm that can actually be reduced, and to be straight about the harm that cannot.

The single most valuable thing is not a test. It is telling the oncology team. Disclosure is what allowed the team caring for that 80-year-old woman on pembrolizumab to identify the real cause of her abnormal liver tests and keep her on a treatment that was working. Without that one piece of information, the same numbers would have looked like immunotherapy-induced hepatitis, and she would likely have lost the drug. Nothing on a lab panel substitutes for that conversation.

Several other protections are decisions, not measurements. None of them make the practice advisable. They remove specific avoidable harms from a situation that remains unadvisable. A complete medication and supplement review can remove P-glycoprotein blockers, including common over-the-counter acid reducers, that amplify ivermectin’s effects on the nervous system. A human pharmaceutical product, rather than a veterinary paste or an unverified overseas seller, reduces the risk of contamination and underdosing. A defined stopping point keeps “a few weeks” from silently becoming a year. And knowing which symptoms mean stop immediately, such as yellowing of the eyes or skin, dark urine, confusion, unsteady walking, visual changes, unusual drowsiness, severe rash or peeling skin, or unexplained bleeding, shortens the time between a problem starting and someone acting on it.

Now the part that usually goes unsaid. Periodic bloodwork detects liver injury and changes in blood counts. It detects almost nothing else on this article’s list. No routine test shows whether ivermectin is raising or lowering the blood level of a targeted therapy or hormonal agent. Nobody is sequencing anyone’s microbiome. No panel captures a small reduction in how well immunotherapy is working, and if that treatment underperforms, the failure will be attributed to the cancer rather than to anything you added. Neurological toxicity from a saturated transport pump shows up as symptoms, not chemistry. Even liver monitoring relies on samples rather than watches, and published cases show how quickly injury can escalate between draws. Supervision lowers some of these risks. It eliminates none of them, and it cannot see most of them.

That is the difference between supervised use and safe use, and it is why ASCO’s position is that this belongs inside a clinical trial, where monitoring is far more intensive than anything a monthly lab draw provides.

Underneath it all is the plainest fact in this article. No completed randomized trial shows that ivermectin improves any cancer outcome in humans. The COVID-19 experience is the cautionary parallel worth remembering: the cell-culture signal was striking, the enthusiasm was sincere, and the large randomized trials found no benefit, with one meta-analysis suggesting higher hospitalization risk at higher cumulative doses.

I take the desire for every possible edge seriously, because it comes from the right place. But we are stewards of bodies that came with real protective systems already installed, the liver’s clearance pathways and the barrier pumps among them, and those systems have limits that do not announce themselves before they are exceeded. What an article like this can offer is not a yes or a no, and certainly not a promise that careful monitoring makes this safe. It is a clear-eyed accounting of the trade, so that the decision gets made with full information rather than half of it.

If you are taking ivermectin now, or considering it, tell your oncology team. Disclosure does not make the practice safe, and nothing here should be read as endorsing it. It simply keeps the people responsible for your care from working blind, because a treatment plan built on incomplete information can fail for reasons nobody can trace.

References

1. American Society of Clinical Oncology. ASCO Clinical Notice: Recommending Against Ivermectin and Fenbendazole for Cancer Treatment, Outside of Clinical Trials. ASCO Connection. May 2026.
2. Baudou E, Lespine A, Durrieu G, et al. Serious ivermectin toxicity and human ABCB1 nonsense mutations. N Engl J Med. 2020;383(8):787-789.
3. Belo TCA, Santos NCM, Souto BS, et al. Ivermectin-induced bacterial gut dysbiosis does not increase susceptibility to Pseudomonas aeruginosa lung infection but exacerbates liver damage. Microbes Infect. 2023;25:105080.
4. Belo TCA, Silva EN, Corsetti PP, de Almeida LA. Ivermectin impact over gut microbiota diversity: a comprehensive and updated analysis from pre-clinical and clinical evaluations. The Microbe. 2025;7:100318.
5. Bomze D, Sprecher E, Geller S. Severe cutaneous adverse reactions associated with systemic ivermectin: a pharmacovigilance analysis. J Dermatol. 2022;49(8):769-774.
6. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
7. Chandler RE. Serious neurological adverse events after ivermectin: do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. 2018;98(2):382-388.
8. Draganov D, Han Z, Rana A, Bennett N, Irvine DJ, Lee PP. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer. 2021;7(1):22.
9. Gilene S, Haacker L, Rutan H, Pressey JG. The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient. Pediatr Blood Cancer. 2025;72(9):e31876.
10. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002;42(10):1122-1133.
11. Hernandez AV, Liu A, Roman YM, et al. Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: a systematic review and meta-analysis. Int J Antimicrob Agents. 2024;64(2):107248.
12. Hoang R, Temple C, Correia MS, et al. Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19. Clin Toxicol. 2022;60(12):1350-1355.
13. Johnson SB, Park HS, Gross CP, Yu JB. Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. JAMA Oncol. 2018;4(10):1375-1381.
14. Johnson SB, Park HS, Gross CP, Yu JB. Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst. 2018;110(1):121-124.
15. Klotz U, Ogbuokiri JE, Okonkwo PO. Ivermectin binds avidly to plasma proteins. Eur J Clin Pharmacol. 1990;39(6):607-608.
16. Liu L, Mahalak KK, Bobokalonov JT, et al. Impact of ivermectin on the gut microbial ecosystem. Int J Mol Sci. 2023;24(22):16125.
17. Marjanović V, Medić D, Marjanović D, et al. High doses of ivermectin cause toxic effects after short-term oral administration in rats. Slov Vet Res. 2024;61(4):281-290.
18. Ménez C, Mselli-Lakhal L, Foucaud-Vignault M, Balaguer P, Alvinerie M, Lespine A. Ivermectin induces P-glycoprotein expression and function through mRNA stabilization in murine hepatocyte cell line. Biochem Pharmacol. 2012;83(2):269-278.
19. Ottesen A, Kocurek B, Deaver C, et al. Fecal microbiomes of laboratory beagles receiving antiparasitic formulations in an experimental setting. Microbiol Resour Announc. 2024;13(2):e0086023.
20. Patel Y, Chawla J, Parmar MS. Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential? Curr Oncol Rep. 2025.
21. Pouliot JF, L’Heureux F, Liu Z, Prichard RK, Georges E. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997;53(1):17-25.
22. Powderly GE, Hassevoort K, Loy M, Balonier J, Sievers C. Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report. Cureus. 2026;18(5):e108896.
23. Reis G, Silva EASM, Silva DCM, et al. Effect of early treatment with ivermectin among patients with COVID-19. N Engl J Med. 2022;386(18):1721-1731.
24. Rendic SP. Metabolism and interactions of ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects. Arch Toxicol. 2021;95(5):1535-1546.
25. Robalino KN, Vivanco-Galván O, Romero-Benavides JC, Jiménez-Gaona Y. Ivermectin as an alternative anticancer agent: a review of its chemical properties and therapeutic potential. Pharmaceuticals (Basel). 2025;18(10):1459.
26. Sanford NN, Sher DJ, Xu X, et al. Prevalence and nondisclosure of complementary and alternative medicine use in patients with cancer and cancer survivors in the United States. JAMA Oncol. 2019;5(5):735-737.
27. Schmith VD, Zhou J, Lohmer LRL. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clin Pharmacol Ther. 2020;108(4):762-765.
28. Temple C, Hoang R, Hendrickson RG. Toxic effects from ivermectin use associated with prevention and treatment of COVID-19. N Engl J Med. 2021;385(23):2197-2198.
29. Thakurdesai A, Rivera-Matos L, Nagra N, Busch B, Mais DD, Cave MC. Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication, fenbendazole. ACG Case Rep J. 2024;11(5):e01354.
30. US Food and Drug Administration. Stromectol (ivermectin) tablets: prescribing information. Silver Spring, MD: US Food and Drug Administration.
31. Vanhee C, Jacobs B, Kamugisha A, et al. Substandard and falsified ivermectin tablets obtained for self-medication during the COVID-19 pandemic as a source of potential harm. Drug Test Anal. 2024;16(9):957-967.
32. Yamaguchi T, Shimizu J, Oya Y, Horio Y, Hida T. Drug-induced liver injury in a patient with nonsmall cell lung cancer after the self-administration of fenbendazole based on social media information. Case Rep Oncol. 2021;14(2):886-891.
33. Yilmaz S, Göktaş B, Ateş İ, Çelik M. Ivermectin toxicity in humans and animals: clinical spectrum, mechanisms, and management. J Appl Toxicol. 2026;46(6):1856-1870.
34. Zhang P, Li Y, Xu W, et al. Immunotoxicity induced by ivermectin is associated with NF-kB signaling pathway on macrophages. Chemosphere. 2022;289:133087.